Novel Breast Probe Reduces Repeat Breast Cancer Surgeries

Publication
Article
OncologyONCOLOGY Vol 22 No 6
Volume 22
Issue 6

A novel intraoperative breast cancer probe is showing significant promise in the reduction of repeat procedures in patients undergoing breast-conserving surgeries, according to a study presented at the ASBS meeting.

A novel intraoperative breast cancer probe is showing significant promise in the reduction of repeat procedures in patients undergoing breast-conserving surgeries, according to a study presented at the ASBS meeting. Using radiofrequency spectroscopy technology, the handheld MarginProbe (Dune Medical Devices, Caesarea, Israel) assesses margin malignancy status during an initial lumpectomy and helps avoid repeat procedures by enabling doctors to intraoperatively identify positive margins. Currently, positive tumor margins are identified through postoperative pathology results and are typically corrected with second surgeries, incurring added patient complication and expense.

The 300-patient randomized clinical trial conducted in 11 Israeli medical centers underscored the safety and clinical benefit of the MarginProbe system in the intraoperative detection of tumors at the resection margins in patients undergoing breast-conservation surgery. The study compared the performance of 35 surgeons operating on patients with and without use of the device. Use of the probe resulted in a 56% reduction in repeat lumpectomies. No statistically significant difference between the two study arms was seen in the volume of tissue removed.

More Precise Surgery
“This data is significant in demonstrating the potential of radiofrequency spectroscopy and the probe in characterization of cancer at the resection margins and in guiding surgeons towards more precise surgical interventions,” said study investigator Tanir Allweis, MD, of Hadassah Hebrew University Medical Center, Jerusalem. “The reduction of patient complications and discomfort as well as costs associated with repeat breast surgeries is of significant benefit to everyone involved in the treatment of breast disease.”

The device consists of a sterile, handheld probe and portable console. As the tip of the probe is applied to excised lumpectomy tissue, radiofrequency signals are transmitted into the tissue. After the signals are reflected back to the console, they are analyzed based on a specialized algorithm to determine the presence of malignant tissue in the measured area adjacent to the probe tip.

 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content